The purpose of this study is Safety, Pharmacokinetic Study of PRIC
1. To Compare Pharmacokinetics of PRIC and Pranlukast Dry Syrup 2. To evaluate the safety and tolerability of PRIC and Pranlukast Dry Syrup
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
48
Pranlukast hydrate 50mg
Pranlukast hydrate 225mg/2.25g
Asan Medical Center
Seoul, Songpa-gu, South Korea
Area Under the Curve (AUC) to last time point (t)
Area under the PRIC/Pranlukast dry syrup concentration in blood-time curve from zero to the final
Time frame: 0, 0.5, 0.75, 1, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10 and 12hours postdose
Maximum concentration of drug (Cmax)
The maximum PRIC/Pranlukast dry syrup concentration in blood sampling time t
Time frame: 0, 0.5, 0.75, 1, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10 and 12hours postdose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.